RNTX
Rein Therapeutics Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.09
P/S
0.00
EV/EBITDA
-1.63
DCF Value
$-0.01
FCF Yield
-49.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-281.0%
ROA
-206.4%
ROIC
-120.3%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-32.0M | $-1.22 |
| FY 2025 | $0.00 | $-49.9M | $-1.96 |
| Q3 2025 | $0.00 | $-5.6M | $-0.21 |
| Q2 2025 | $0.00 | $-6.8M | $-0.28 |
Analyst Ratings
View AllConsensus
Hold
Target (Consensus)
$6.00
Target (Median)
$6.00
Target Range
$6.00 - $6.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.40
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.